The taller you are, the more likely you may develop varicose veins

A person’s height may be a risk factor for varicose veins, which can be associated with other health risks.

The taller you are, the more likely you may develop varicose veins
Image: Public Domain

A person’s height and certain qualities that foresee height are related with varicose veins and may give intimations about what makes this condition and ways avoid and treat it.

In excess of 30 million individuals in the United State are evaluated to have varicose veins, which is a typical condition that is progressively being related with genuine wellbeing dangers, including life-limiting ulceration and venous thromboembolism, which is the point at which a blood coagulation shapes inside a vein. Be that as it may, little is thought about what causes varicose vein sickness or how to treat it.

Scientists used the data from a massive long-term study of the UK Biobank, to look for varicose vein risk factors among 413,519 people. In addition, the researchers screened for genetic markers among 337,536 people, 9,577 of whom had varicose vein disease. Researchers confirmed that age, gender, obesity, pregnancy, and history of deep vein thrombosis are risk factors for varicose veins, and also found:

  • Increased height increases the risk for varicose veins;
  • Genes that determine height also influence the development of varicose veins; and
  • There is a strong genetic correlation between deep vein thrombosis and varicose veins.

Lead author Nicholas J. Leeper, M.D., from the Divisions of Vascular Surgery and Cardiovascular Medicine at Stanford University in California, said, “We may be able to leverage what we know about the biology underlying human height and use it to uncover the root causes of varicose vein disease. Ultimately, this may help investigators discover a therapy that can prevent or reverse this common and sometimes debilitating disease.”

“By conducting the largest genetics study ever performed for varicose vein disease, we now have a much better understanding of the biology that is altered in people at risk for the disease. Ultimately, we hope to test whether those factors can be targeted, and potentially prevent or delay the development of disease in at-risk individuals.”

The study is published in the journal Circulation. Co-authors are Eri Fukaya, M.D., Ph.D.; Alyssa M. Flores, B.S.; Daniel Lindholm, M.D., Ph.D.; Stefan Gustafsson, Ph.D.; Daniela Zanetti, Ph.D.; and Erik Ingelsson, M.D., Ph.D. Author disclosures are on the manuscript.